Library

All

All, Press Release, Uncategorized

Quantoom Biosciences installs the first Ntensify™ system for mRNA manufacturing at Afrigen Biologics in Cape Town

Learn more →

All, Press Release, Uncategorized

ImmuneWatch, Quantoom Biosciences and UAntwerp join forces to explore new in vitro and in silico assays that predict T cell responses in vaccines

Learn more →

All, Press Release, Uncategorized

Quantoom Biosciences is growing in France with brand-new facilities for its DNA and enzymes activity located in Evry

Learn more →

All, Case Study

Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis

Learn more →

All, Press Release

Quantoom Biosciences granted $13.9 Million (€12.4 million), to support the development of its novel mRNA manufacturing platform for vaccines and therapeutics

Learn more →

All, Press Release

eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System

Learn more →

All, Press Release

Introducing Quantoom Biosciences, a Univercells company, with the mission to improve access to essential medicines and autonomy in bioproduction through innovation

Learn more →

Press Releases

May 2, 2023 | All, Press Release, Uncategorized

Quantoom Biosciences installs the first Ntensify™ system for mRNA manufacturing at Afrigen Biologics in Cape Town

Learn more →

March 30, 2023 | All, Press Release, Uncategorized

ImmuneWatch, Quantoom Biosciences and UAntwerp join forces to explore new in vitro and in silico assays that predict T cell responses in vaccines

Learn more →

March 2, 2023 | All, Press Release, Uncategorized

Quantoom Biosciences is growing in France with brand-new facilities for its DNA and enzymes activity located in Evry

Learn more →

June 27, 2022 | All, Press Release

New agreement paves way for development of first African-owned COVID-19 vaccine

Learn more →

January 13, 2022 | All, Press Release

Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis

Learn more →

December 20, 2021 | All, Press Release

Quantoom Biosciences granted $13.9 Million (€12.4 million), to support the development of its novel mRNA manufacturing platform for vaccines and therapeutics

Learn more →

Brochures

All, Brochures

Brochure Ntensify mini

Brochure Ntensify mini Ntensify mini, for Drug Discovery and Pre-Clinical Phase. Download the brochure as a pdf: Contact Us

Learn more →

All, Brochures

Brochure Ntensify midi

Brochure Ntensify midi Ntensify midi, for Clinical Phases & commercial production < 7M doses/year. Download the brochure as a pdf: ...

Learn more →

All, Brochures

Brochure Nplify system

Brochure Nplify system Nplify system, for the production of linear DNA. Download the brochure as a pdf: Contact Us

Learn more →

All, Brochures

Brochure on the Nfinity Platform

Brochure on the Nfinity Platform The Ntensify Platform Removes Barriers in mRNA Design and Production. Download the brochure as a ...

Learn more →

Posters

All, Poster

Poster mRNA Health Conference

Poster mRNA Health Conference Download the poster as a pdf: Contact Us

Learn more →

Case Study

All, Case Study

Rabies mRNA Vaccine

Rabies mRNA Vaccine Download the case study as a pdf: Contact Us

Learn more →

Corporate Presentations

Quantoom Biosciences_Non Confidential_2023-01_Final2

Download our Corporate Presentation

Videos

Please accept statistics cookies to watch this video.

Library

All

Quantoom Biosciences installs the first Ntensify™ system for mRNA manufacturing at Afrigen Biologics in Cape Town

ImmuneWatch, Quantoom Biosciences and UAntwerp join forces to explore new in vitro and in silico assays that predict T cell responses in vaccines

Quantoom Biosciences is growing in France with brand-new facilities for its DNA and enzymes activity located in Evry

Rabies mRNA Vaccine

Poster mRNA Health Conference

Brochure Ntensify mini

Brochure Ntensify midi

Brochure Nplify system

Brochure on the Nfinity Platform

New agreement paves way for development of first African-owned COVID-19 vaccine

Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis

Quantoom Biosciences granted $13.9 Million (€12.4 million), to support the development of its novel mRNA manufacturing platform for vaccines and therapeutics

eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System

Introducing Quantoom Biosciences, a Univercells company, with the mission to improve access to essential medicines and autonomy in bioproduction through innovation

Press Releases

Quantoom Biosciences installs the first Ntensify™ system for mRNA manufacturing at Afrigen Biologics in Cape Town

ImmuneWatch, Quantoom Biosciences and UAntwerp join forces to explore new in vitro and in silico assays that predict T cell responses in vaccines

Quantoom Biosciences is growing in France with brand-new facilities for its DNA and enzymes activity located in Evry

New agreement paves way for development of first African-owned COVID-19 vaccine

Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis

Quantoom Biosciences granted $13.9 Million (€12.4 million), to support the development of its novel mRNA manufacturing platform for vaccines and therapeutics

Brochures

Brochure Ntensify mini

Brochure Ntensify midi

Brochure Nplify system

Brochure on the Nfinity Platform

Posters

Poster mRNA Health Conference

Case Study

Rabies mRNA Vaccine

Corporate Presentations

Videos

Navigation

Links

Follow us on social media